Previous 10 | Next 10 |
– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic partners for COVID-19 Coronavirus program – – Collabor...
The outbreak of the novel coronavirus disease COVID-19 rapidly spreads around the globe. The various biotechnology firms, scientists, and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective...
The following slide deck was published by Cocrystal Pharma, Inc. in conjunction with this Read more ...
SAExploration Holdings (NASDAQ: SAEX ) +177% on $27M new project in Greece. More news on: SAExploration Holdings, Inc., B.O.S. Better Online Solutions Ltd., The Peck Company Holdings, Inc., Stocks on the move, Read more ...
Cocrystal Pharma (NASDAQ: COCP ) has expanded its license agreement with Kansas State University Research Foundation (“KSURF”) to include rights to additional preclinical leads and further develop certain proprietary broad-spectrum antiviral compounds for the treatment o...
Are These On Your Penny Stocks Watch List In April? Whether you passively invest in the market or actively day trade penny stocks and large-caps, the goal is the same: make money. While businesses go public to raise money by giving up ownership of small pieces of their companies, investors w...
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have demonstrated strong proof-of-concept and excellent efficacy data in MERS-CoV animal mo...
- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - BOTHELL, WA, April 20, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc ....
Cocrystal Pharma (NASDAQ: COCP ) has filed a prospectus for a $150M mixed shelf offering. More news on: Cocrystal Pharma, Inc., Healthcare stocks news, , Read more ...
Obalon Therapeutics (NASDAQ: OBLN ) -25% . More news on: Obalon Therapeutics, Inc., NeuroMetrix, Inc., Cocrystal Pharma, Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Cocrystal Pharma Inc. Company Name:
COCP Stock Symbol:
NASDAQ Market:
Cocrystal Pharma Inc. Website:
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the single-ascending dose (SAD) cohorts of the Phase 1 study in healthy volunteers wit...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently ...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected ...